(Total Views: 451)
Posted On: 06/14/2019 4:17:41 PM
Post# of 8445
Sofpulse, a PEMF device that BIEL used as a Predicate for its successful 2017 FDA 510k, is aggressively targeting the Hospital Market as an Opioid Alternative. They are hiring sales reps and making distributor agreements.
Their CEO feels that Hospitals are a potential $300 million market for Sofpulse which sells for about $250.
The Sofpulse and RecoveryRx have a very similar construction with a small electronics module and an antenna to distribute the RF signal.
When RecoveryRx is FDA Cleared for Post-op use BIEL could be offering a similar PEMF device to Hospitals at a fraction of the Sofpulse cost.
https://www.globenewswire.com/news-release/20...itals.html
Their CEO feels that Hospitals are a potential $300 million market for Sofpulse which sells for about $250.
The Sofpulse and RecoveryRx have a very similar construction with a small electronics module and an antenna to distribute the RF signal.
When RecoveryRx is FDA Cleared for Post-op use BIEL could be offering a similar PEMF device to Hospitals at a fraction of the Sofpulse cost.
https://www.globenewswire.com/news-release/20...itals.html
(0)
(0)
